Prophylactic management of children at risk for recurrent upper respiratory infections: The Preventia I Study

Clinical and Experimental Allergy

Volumn 34, Issue 11, 2004, Pages 1665-1672

  Grimfeld, Alain ^a   Holgate, S T ^b   Canonica, G W ^c   Bonini, S ^d   Borres, M P ^e   Adam, D ^f   Canseco Gonzalez, C ^g   Lobaton, P ^h   Patel, P ⁱ   Szczeklik, A ^j   Danzig, M R ^k   Roman, I ^l   Bismut, H ^m   Czarlewski, W ⁿ  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF GENOA   (Italy)

^d CNR   (Italy)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^h UNIVERSITY OF CÁDIZ   (Spain)

ⁱ Allied Clinical   (Canada)

^j JAGIELLONIAN UNIVERSITY   (Poland)

^k MERCK RESEARCH LABORATORIES   (United States)

^l Target Research Associates   (United States)

^m Strategik and Numerik   (France)

ⁿ Schering Plough   (France)

more..

Author keywords

Airway hyper reactivity; Asthma; Child; ENT infections; ICAM 1; Loratadine; Prevention; Psychomotor development; Rhinovirus; Wheezing

Indexed keywords

LORATADINE; PLACEBO;

ARTICLE; ASTHMA; BRONCHITIS; CARDIOVASCULAR SYMPTOM; CHICKENPOX; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROENTERITIS; HUMAN; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OTITIS MEDIA; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SEDATION; SIDE EFFECT; SINUS ARRHYTHMIA; SINUS BRADYCARDIA; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; WHEEZING;

ANTI-ALLERGIC AGENTS; ASTHMA; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; INFANT; LORATADINE; MALE; RECURRENCE; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 9244242519     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2004.02098.x     Document Type: Article

References (34)

1. European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur Respir J 1996; 9:687-95.
2. Strachan DP, Sibbald B, Weiland S et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997; 8:161-76, 1989; 299:1259-60.
3. Strachan DP, Sibbald B, Weiland S et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997; 8:161-76, 1989; 299:1259-60.
4. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 3514:1225-32.
5. von Mutius E. The environmental predictors of allergic disease. J Allergy Clin Immunol 2000; 105:9-19.
6. Platts-Mills TA, Rakes G, Heymann PW. The relevance of allergen exposure to the development of asthma in childhood. J Allergy Clin Immunol 2000; 105:503-8.
7. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332:133-8.
8. Illi S, von Mutius E, Lau S et al. Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. Br Med J 2001; 322:390-5.
9. Strachan DP. Hay fever, hygiene and household size. Br Med J 1989; 299:1259-60.
10. von Mutius E, Martinez FD, Fritzsch C, Nicolai T, Roell G, Thiemann HH. Prevalence of asthma and atopy in two areas of West and East Germany. Am J Respir Crit Care 1994; 24:826-35.
11. Matricardi PM, Rosmini F, Riondino S et al. Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. Br Med J 2000; 320:412-7.
12. Matricardi PM, Rosmini F, Panetta V, Ferrigno L, Bonini S. Hay fever and asthma in relation to markers of infection in the United States. J Allergy Clin Immunol 2002; 110:381-7.
13. Nystad W, Skrondal A, Magnus P. Day care attendance, recurrent respiratory tract infections and asthma. Int J Epidemiol 1999; 28:882-7.
14. Nafstad P, Hagen JA, Oie L, Magnus P, Jaakkola JJ. Day care centers and respiratory health. Pediatrics 1999; 103:753-8.
15. Pekkanen J, Remes S, Kajosaari M, Husman T, Soininen L. Infections in early childhood and risk of atopic disease. Acta Paediatr 1999; 88:710-4.
16. Kramer U, Heinrich J, Wjst M, Wichmann HE. Age of entry to day nursery and allergy in later childhood. Lancet 1999; 353:450-4.
17. Sims DG, Downham MA, Gardner PS, Webb JK, Weightman D. Study of 8-year-old children with a history of respiratory syncytial virus bronchiolitis in infancy. Br Med J 1978; 1:11-4.
18. Pullan CR, Hey EN. Wheezing, asthma and pulmonary dysfunction 10 years after infection with syncytial virus in infancy. Br Med J 1982; 284:1665-9.
19. Busse W, Castleman W. Infections. Am J Respir Crit Care Med 1995; 151:520-2.
20. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Bjorksten B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995; 95:500-5.
21. Doyle WJ, Skoner DP, Seroky JT, Fireman P, Gwaltney JM. Effect of experimental rhinovirus-39 infection on the nasal response to histamine and cold air challenges in allergic and non-allergic subjects. J Allergy Clin Immunol 1994; 93:534-42.
22. Calhoun WJ, Dick EC, Schwartz LB, Busse WW. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest 1994; 94:2200-8.
23. Frick OL, German DF, Mills J. Development of allergy in children. I. Association with virus infection. J Allergy Clin Immunol 1979; 63:228-41.
24. Anderson LJ, Tsou C, Potter C et al. Cytokine response to respiratory syncytial virus stimulation of human peripheral blood mononuclear cells. J Infect Dis 1994; 170:1201-8.
25. Gern JE, Busse W. The effects of rhinovirus infections on allergy airway responses. Am J Respir Crit Care Med 1995; 152:540-5.
26. Canonica GW, Ciprandi G, Buscaglia S, Pesce G, Bagnasco M. Adhesion molecules of allergic inflammation: recent insights into their functional roles. Allergy 1994; 49:135-41.
27. Papi A, Johnston SL. Respiratory epithelial cell expression of vascular cell adhesion molecule-1 and its up-regulation by rhinovirus infection via NF-kappaB and GATA transcription factors. J Biol Chem 1999; 274:30041-51.
28. Kreutner W, Chapman RW, Gulbenkian A, Siegel MI. Antiallergic activity of loratadine, a non-sedating antihistamine. Allergy 1987; 42:57-63.
29. Miadonna A, Milazzo N, Lorini M, Marchesi E, Tedeschi A. Inhibitory effect of the H1 antagonist loratadine on histamine release from human basophils. Int Arch Allergy Immunol 1994; 105:12-7.
30. Vignola AM, Crampette L, Mondain M et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995; 50:200-3.
31. Ciprandi G, Catrullo A, Cerqueti P, Tosca M, Fiorino N, Canonica GW. Loratadine reduces the expression of ICAM-1. Allergy 1998; 53:545-6.
32. Papi A, Papadopoulos NG, Stanciu LA, Degitz K, Holgate ST, Johnston SL. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. J Allergy Clin Immunol 2001; 108:221-8.
33. Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993; 71:121-6.
34. Hey JA, del Prado M, Egan RW, Sherwood J, Kreutner W. Loratadine produces antihistamine activity without adverse CNS, ECG or cardiovascular effects in guinea pigs. Comparative studies with terfenadine and sedating antihistamines. Int Arch Allergy Immunol 1995; 107:418-9.